Clinical trial Recruiting at 1 site Observational Ages 60 to 95

Risk markers of arterial aging in older adults — Paris Prospective III-2

Official title: Risk Markers of Arterial Aging and Subsequent Risk of Cardiovascular Diseases and Beyond. The Paris Prospective Study III-2

Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT06079424 · Data updated 2026-11-12

This follow-up will re-examine people who took part in the original Paris cohort to measure changes in arterial stiffness and baroreflex over about 12–16 years and see if those changes predict later heart and blood vessel disease.

More Arterial Stiffness trials

Quick facts

Study typeObservational
Ages60 Years to 95 Years
SexAll
Enrollment7500 (estimated)
SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Government
Locations1 site (Paris)
StatusRecruiting
StartedJune 20, 2025
Main results expectedMay 2031
Study endsDecember 2033
Registry record updatedSeptember 17, 2026
Trial IDNCT06079424 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are original PPS3 participants who are alive, able to attend the Paris follow-up visit, and who sign the informed consent for PPS3-2.

Probably not a fit

People who are institutionalized or under legal guardianship or cannot attend the follow-up visit are excluded and would not be able to participate or benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project re-invites survivors and original participants from the Paris Prospective Study III for a second physical exam roughly 12–16 years after baseline to describe the dynamics of vascular aging and baroreflex sensitivity. Participants will undergo high-precision carotid echo-tracking and a new ultrafast radial artery echo to measure arterial aging parameters in large and medium-sized arteries. Blood samples may be collected and biobanked depending on funding. The study will link changes in these vascular measures to subsequent cardiovascular disease events in the well-characterized cohort of 10,157 adults who were 50–75 years old at baseline.

Why it matters

Potential benefit: If successful, the study could identify early vascular aging markers that help predict and prevent future cardiovascular disease.

How similar studies have gone: Previous cohort research has linked arterial stiffness to cardiovascular risk, but long-term repeated measures using high-precision carotid echo-tracking and ultrafast radial echo over a 12–16 year interval are relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Being enrolled in PPS3 and having signed an informed consent for PPS3-2

Exclusion Criteria:

* Institutionalized participants
* Participants under guardianship
* Participants under judicial safeguard measure

Where it's running

  • Centre d'Investigation Précliniques
    Paris, France
    Recruiting

Study contacts

  • Principal investigator: Jean-Philippe Empana, MD, PhD — Institut National de la Santé Et de la Recherche Médicale, France
  • Study coordinator: Jean-Philippe Empana, MD, PhD
  • Email: jean-philippe.empana@inserm.fr
  • Phone: 33153988020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.